Literature DB >> 7767949

Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol.

G Kumar1, S Ray, T Walle, Y Huang, M Willingham, S Self, K Bhalla.   

Abstract

Taxol is metabolized by the liver microsomal cytochrome P450 enzyme system into its principal metabolite 6 alpha-hydroxytaxol (6HT). In the present in vitro studies 6HT was compared to taxol with respect to its effects on tubulin depolymerization, mitotic arrest, clonogenic survival and apoptosis in HL-60 cells. 6HT was generated by incubating taxol with human liver microsomes in a NADPH-generating system. HL-60 cells were incubated for 24 h with either taxol or 6HT, washed and placed in drug-free suspension or cultured for colony growth in agarose. For the suspension and colony culture growth of the cells, the IC50 concentrations of 6HT were 500 +/- 46 and 350 +/- 37 nM, while those of taxol were 3.2 +/- 0.2 and 2.8 +/- 0.5 nM, respectively. Immediately after a 24-h exposure of HL-60 cells to 50 nM taxol, electrophoresis of genomic DNA from HL-60 cells revealed an internucleosomal DNA fragmentation 'ladder'. In addition, 39% of the cells were arrested in mitosis and 16% showed the morphologic features of apoptosis. In contrast, an identical treatment with 6HT resulted in the mitotic arrest of only 2.8% of the cells, with 4.0% displaying apoptosis (P < 0.01); internucleosomal DNA fragmentation was not observed. 6HT was also significantly less effective than taxol in inhibiting the temperature-induced depolymerization of microtubules in a cell-free system. However, at equipotent concentrations, the effect of 6HT on tubulin depolymerization, mitotic arrest or apoptosis was similar to that of taxol. In addition, at concentrations of taxol or 6HT at or below their IC50, there was little tubulin depolymerization, mitotic arrest or apoptosis. The results presented here show that the biotransformation of taxol to 6HT substantially detoxifies taxol.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767949     DOI: 10.1007/BF00689197

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Reversible assembly purification of microtubules without assembly-promoting agents and further purification of tubulin, microtubule-associated proteins, and MAP fragments.

Authors:  R B Vallee
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

2.  Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxanes.

Authors:  J Parness; D G Kingston; R G Powell; C Harracksingh; S B Horwitz
Journal:  Biochem Biophys Res Commun       Date:  1982-04-14       Impact factor: 3.575

3.  6 alpha-Hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes.

Authors:  G N Kumar; J E Oatis; K R Thornburg; F J Heldrich; E S Hazard; T Walle
Journal:  Drug Metab Dispos       Date:  1994 Jan-Feb       Impact factor: 3.922

4.  Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia.

Authors:  R Gallagher; S Collins; J Trujillo; K McCredie; M Ahearn; S Tsai; R Metzgar; G Aulakh; R Ting; F Ruscetti; R Gallo
Journal:  Blood       Date:  1979-09       Impact factor: 22.113

5.  Phase I and pharmacodynamic study of taxol in refractory acute leukemias.

Authors:  E K Rowinsky; P J Burke; J E Karp; R W Tucker; D S Ettinger; R C Donehower
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

6.  Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau.

Authors:  R B Dye; S P Fink; R C Williams
Journal:  J Biol Chem       Date:  1993-04-05       Impact factor: 5.157

7.  Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells.

Authors:  K Bhalla; A M Ibrado; E Tourkina; C Tang; M E Mahoney; Y Huang
Journal:  Leukemia       Date:  1993-04       Impact factor: 11.528

8.  Taxol stabilizes microtubules in mouse fibroblast cells.

Authors:  P B Schiff; S B Horwitz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.

Authors:  G N Kumar; U K Walle; T Walle
Journal:  J Pharmacol Exp Ther       Date:  1994-03       Impact factor: 4.030

10.  Isolation, structural determination, and biological activity of 6 alpha-hydroxytaxol, the principal human metabolite of taxol.

Authors:  J W Harris; A Katki; L W Anderson; G N Chmurny; J V Paukstelis; J M Collins
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

View more
  10 in total

Review 1.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.

Authors:  Troels K Bergmann; Henrik Gréen; Charlotte Brasch-Andersen; Mansoor R Mirza; Jørn Herrstedt; Berit Hølund; Andreas du Bois; Per Damkier; Werner Vach; Kim Brosen; Curt Peterson
Journal:  Eur J Clin Pharmacol       Date:  2011-02-16       Impact factor: 2.953

Review 5.  Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer.

Authors:  R Danesi; P F Conte; M Del Tacca
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

6.  Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.

Authors:  Milly E de Jonge; Alwin Dr Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

7.  Human liver microsomal metabolism of paclitaxel and drug interactions.

Authors:  P B Desai; J Z Duan; Y W Zhu; S Kouzi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

8.  Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.

Authors:  Augusto Pessina; Arianna Bonomi; Valentina Coccè; Gloria Invernici; Stefania Navone; Loredana Cavicchini; Francesca Sisto; Maura Ferrari; Lucia Viganò; Alberta Locatelli; Emilio Ciusani; Graziella Cappelletti; Daniele Cartelli; Caruso Arnaldo; Eugenio Parati; Giovanni Marfia; Roberto Pallini; Maria Laura Falchetti; Giulio Alessandri
Journal:  PLoS One       Date:  2011-12-20       Impact factor: 3.240

9.  Automated Large-Scale Production of Paclitaxel Loaded Mesenchymal Stromal Cells for Cell Therapy Applications.

Authors:  Daniela Lisini; Sara Nava; Simona Frigerio; Simona Pogliani; Guido Maronati; Angela Marcianti; Valentina Coccè; Gianpietro Bondiolotti; Loredana Cavicchini; Francesca Paino; Francesco Petrella; Giulio Alessandri; Eugenio A Parati; Augusto Pessina
Journal:  Pharmaceutics       Date:  2020-04-30       Impact factor: 6.321

10.  The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel.

Authors:  Ippei Fukada; Yoshinori Ito; Kokoro Kobayashi; Tomoko Shibayama; Shunji Takahashi; Rie Horii; Futoshi Akiyama; Takuji Iwase; Shinji Ohno
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.